<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260779</url>
  </required_header>
  <id_info>
    <org_study_id>PV-10-EA-02</org_study_id>
    <nct_id>NCT01260779</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors</brief_title>
  <official_title>Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provectus Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provectus Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This compassionate use protocol provides expanded access for investigational use of PV-10 in
      cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is
      no comparable or satisfactory approved alternative therapy and whom, in the opinion of the
      investigator, may benefit from PV-10 administration.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory</condition>
  <condition>Approved Alternative Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PV-10 (10% rose bengal disodium)</intervention_name>
    <description>Intralesional injection for chemoablation of cutaneous or subcutaneous lesions</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older, male or female.

          2. Histologically or cytologically confirmed cancer where there is no comparable or
             satisfactory approved alternative therapy specific to cutaneous or subcutaneous
             tumors.

          3. Performance Status: ECOG 0-2.

          4. Life Expectancy: At least 6 months.

          5. Blood Chemistry:

               -  Creatinine ≤ 3 times the upper limit of normal (ULN).

               -  Total bilirubin ≤ 3 times the upper limit of normal (ULN).

               -  AST/ALT/ALP ≤ 5 times the upper limit of normal (ULN).

          6. Thyroid Function

               -  Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum
                  thyroxine) and THS (serum thyrotropin) ≤ grade 2 abnormality.

          7. Renal Function

               -  Subjects must have adequate renal function in the opinion of the Investigator
                  with no clinically significant renal impairment or uncontrolled renal disease.

        Exclusion Criteria:

          1. Cancer patients who are eligible for an existing PV-10 clinical trial.

          2. Certain photosensitizing agents within 5 half-lives prior to PV-10 administration.

          3. Concurrent or Intercurrent Illness:

               -  Subjects with uncontrolled diabetes or extremity complications due to diabetes.

               -  Subjects with severe peripheral vascular disease.

               -  Subjects with significant concurrent or intercurrent illness, psychiatric
                  disorders, or alcohol or chemical dependence that would, in the opinion of the
                  Investigator, compromise their safety or compliance or interfere with
                  interpretation of study results.

               -  Subjects with uncontrolled thyroid disease, goiter, partial thyroidectomy,
                  radioiodine- or surgically-treated Graves' hyperthyroidism or cystic fibrosis.

               -  Subjects with clinically significant acute or unstable cardiovascular, (stroke),
                  renal, gastrointestinal, pulmonary, immunological (with the exception of the
                  presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine,
                  or central nervous system disorders.

          4. Pregnancy:

               -  Female subjects who are pregnant or lactating.

               -  Female subjects who have positive serum ßHCG pregnancy test taken within 7 days
                  of PV-10 administration.

               -  Fertile subjects who are not using effective contraception.

          5. Investigational Agents:

               -  Subjects who have received investigational agents within 4 weeks (or 5
                  half-lives) of study administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney (North Sydney and Camperdown)</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Cancer Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

